Hashmat Sayed Zohori Bahrami, Rasmus Bo Hasselbalch, Helle Søholm, Jakob Hartvig Thomsen, Mathias Sørgaard, Klaus Fuglsang Kofoed, Nana Valeur, Søren Boesgaard, Natasha Alexandria Sarah Fry, Jacob Eifer Møller, Anna Axelsson Raja, Lars Køber, Kasper Iversen, Helge Rasmussen, Henning Bundgaard
Diastolic dysfunction (DD) in heart failure (HF) is associated with increased myocardial cytosolic calcium, and calcium-efflux via the sodium-calcium-exchanger depends on the sodium gradient. Beta-3-adrenoceptor (β3-AR) agonists lower cytosolic sodium and have reversed organ congestion. Accordingly, β3-AR agonists might improve diastolic function, which we aimed to assess. In a first-in-man, randomized, double-blinded trial, we assigned 70 patients with HF with reduced ejection fraction (HFrEF), NYHA II-III, and LVEF<40% to receive the β3-AR agonist mirabegron (300 mg/day) or placebo for six months, in addition to recommended HF therapy...
March 5, 2024: Journal of Cardiovascular Pharmacology